CUE-101 / CUE-100 Series (representative)
HPV+ Head and Neck Cancer / Solid Tumors
Phase 1/2Active
Key Facts
About Cue Biopharma
Cue Biopharma is pioneering precision immunotherapies through its proprietary Immuno-STAT™ (Selective Targeting and Alteration of T Cells) platform. The company engineers biologics that mimic natural immune signals to selectively activate or suppress specific T cell populations, offering a targeted approach for autoimmune diseases and cancer. With a leadership team boasting deep experience from Novartis, Johnson & Johnson, and other industry leaders, Cue has secured strategic partnerships with Boehringer Ingelheim and ImmunoScape to advance its pipeline and technology.
View full company profile